FOLH1 and neoplasm: The radiopharmaceutical demonstrated high affinity for both receptors (IC50 ≈ 3–6 nM), and in vivo studies in GRPR+/PSMA+ tumor-bearing mouse models showed high tumor uptake (~7.5% ID/g at 1 h) and low off-target accumulation, indicating an improved theranostic profile compared to the corresponding monomers [21].